Integrated workflows Opportunity to promote gene-to-structure offerings and seamless protein production integration with cryo-EM, leveraging the newly expanded capabilities from the Proteos acquisition and TrueCourse Biosciences launch to attract pharma and biotech clients seeking end-to-end discovery services.

Market leadership Position NIS as the top cryo-EM provider in North America with the longest history, a strong platform for high-value collaborations, and a differentiator for customers needing reliable, high-throughput structure determination and rapid timelines.

Expansion partnerships Capitalize on recent and upcoming collaborations such as the LNP Alliance and TrueCourse Biosciences to cross-sell lipid nanoparticle expertise, protein production, and structure determination to biotech firms pursuing RNA therapeutics, vaccines, and delivery platforms.

Growth financing Leverage Series B1 funding and growing revenue to approach mid-market and late-stage biotech companies for scale-up projects, offering enhanced capabilities, GMP-compliant services, and accelerated timelines to de-risk drug discovery programs.

Technology stack Highlight investments in AWS, high-end cryo-EM workflows, and data management tools to reassure potential clients about data security, scalability, and integration with their existing IT and LIMS ecosystems.